{"title":"Flavonoids and flavonoid-based nanoparticles for the treatment of arthritis.","authors":"Sanchit Dhankhar, Jatin Kumar, Samrat Chauhan, Ishrat Zahoor, Shahid Nazir Wani, Monika Saini, Jamila Akter Borsha, Sabina Yasmin, Mohammad Yousuf Ansari","doi":"10.1007/s10787-025-01722-0","DOIUrl":null,"url":null,"abstract":"<p><p>Arthritis is an autoimmune disorder that predominantly causes inflammation and impacts peripheral joints. Even though immunosuppressive and NSAIDs or non-steroidal anti-inflammatory medicines are implemented for the management of this disorder, sbut they carry some severe side effects along with them. Therefore, society requires treatment with fewer side effects and powerful anti-arthritic properties, such as flavonoids. These are the most prevalent phenolic compounds found in nature that have potent antioxidant, and immunomodulatory activity and there are several bioactive flavonoids that carry potent anti-inflammatory properties. Nevertheless, only a handful has reached their clinical use. Still, in both clinical and preclinical models of arthritis, flavonoids found in the diet have been shown to reduce swelling in joints and arthritis symptoms. There are only a few scientific studies regarding their mechanisms of action in arthritis. However, the arthritic potential of dietary flavonoids is insufficient because of their limited solubility, absorption, and fast metabolism. Nanocarriers may enhance the bioavailability of flavonoids. This review examines the therapeutic effects of the most prevalent and abundant flavonoid groups on arthritis. Specifically, the modes of action of the most important flavonoids on the chemical messengers in the body that contribute to the signalling of joint inflammation-related indicators of arthritis are discussed in more detail.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01722-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Arthritis is an autoimmune disorder that predominantly causes inflammation and impacts peripheral joints. Even though immunosuppressive and NSAIDs or non-steroidal anti-inflammatory medicines are implemented for the management of this disorder, sbut they carry some severe side effects along with them. Therefore, society requires treatment with fewer side effects and powerful anti-arthritic properties, such as flavonoids. These are the most prevalent phenolic compounds found in nature that have potent antioxidant, and immunomodulatory activity and there are several bioactive flavonoids that carry potent anti-inflammatory properties. Nevertheless, only a handful has reached their clinical use. Still, in both clinical and preclinical models of arthritis, flavonoids found in the diet have been shown to reduce swelling in joints and arthritis symptoms. There are only a few scientific studies regarding their mechanisms of action in arthritis. However, the arthritic potential of dietary flavonoids is insufficient because of their limited solubility, absorption, and fast metabolism. Nanocarriers may enhance the bioavailability of flavonoids. This review examines the therapeutic effects of the most prevalent and abundant flavonoid groups on arthritis. Specifically, the modes of action of the most important flavonoids on the chemical messengers in the body that contribute to the signalling of joint inflammation-related indicators of arthritis are discussed in more detail.
期刊介绍：
Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas:
-Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states
-Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs
-Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents
-Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain
-Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs
-Muscle-immune interactions during inflammation [...]
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
